• Explore /
  • Poster
  • / Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC).

Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC).

Abstract Poster

Authors

Martin Chasen

Martin Chasen

Palliative Care, at The Ottawa Hospital Cancer Centre and the Medical Director of the Palliative Rehabilitation Program at the Élisabeth Bruyère Hospital, Ottawa, Ottawa, ON, Canada

Martin Chasen , Laszlo Urban , Ian Schnadig , Bernardo Leon Rapoport , Allen Poma , Sujata Arora , Rudolph M. Navari , Lee Steven Schwartzberg , Cesare Gridelli

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Patient and Survivor Care

Track

Patient and Survivor Care

Sub Track

Symptom Management/Supportive Care

Clinical Trial Registration Number

NCT01500213; NCT01499849; NCT01500226

Citation

J Clin Oncol 33, 2015 (suppl; abstr 9615)

DOI

10.1200/jco.2015.33.15_suppl.9615

Abstract #

9615

Poster Bd #

274

Abstract Disclosures

Similar Posters

First Author: Ian D. Schnadig

Poster

2016 Palliative and Supportive Care in Oncology Symposium

Rolapitant for the prevention of nausea in patients receiving moderately or highly emetogenic chemotherapy.

Rolapitant for the prevention of nausea in patients receiving moderately or highly emetogenic chemotherapy.

First Author: Rudolph M. Navari

First Author: Daniel Powers

First Author: Paul Joseph Hesketh